購(gòu)物車(chē) 
-
溴沙定
- names：
Broxaldine
- CAS號(hào)：
3684-46-6
MDL Number： - MF(分子式)： C17H11Br2NO2 MW(分子量)： 421.08
- EINECS:222-971-1 Reaxys Number:
- Pubchem ID:77262 Brand:BIOFOUNT
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原蟲(chóng)藥。Broxaldine抑制艱難梭菌的MIC值為4 µM，并具有抗真菌作用。
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000784-50mg | 50mg | >98.0% | ￥ 0.00 | ￥ 0.00 | Backorder | ￥ 0.00 | ||
| YZM000784-10mg | 10mg | >98.0% | ￥ 487.50 | ￥ 487.50 | 2-3天 | ￥ 0.00 |
- 大包裝詢(xún)價(jià) 提供各種包裝，敬請(qǐng)垂詢(xún)
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)
| 中文別名 | 溴沙定(3684-46-6);溴索丁;二溴甲喹苯酯;5,7-二溴-2-甲基-8-喹啉基苯甲酸酯;5,7-二溴-8-羥基喹那啶;5,7-二溴-8-苯甲酰氧基奎尼丁; 5,7-二溴-2-甲基-8-酚基苯甲酸酯； |
| 英文別名 | Broxaldine(3684-46-6);5,7-dibromo-2-methyl-8-quinolylbenzoate;Broxaldine;Brobenzoxaldine; 5,7-Dibromo-8-benzoyloxyquinaldine; 5,7-Dibrom-2-methyl-8-chinolyl benzoat; |
| CAS號(hào) | 3684-46-6 |
| Inchi | InChI=1S/C17H11Br2NO2/c1-10-7-8-12-13(18)9-14(19)16(15(12)20-10)22-17(21)11-5-3-2-4-6-11/h2-9H,1H3 |
| InchiKey | IJTPLVAAROHGGB-UHFFFAOYSA-N |
| 分子式 Formula | C17H11Br2NO2 |
| 分子量 Molecular Weight | 421.08 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 42.86 mg/mL(101.79 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類(lèi)存儲(chǔ)，并交于專(zhuān)業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:溴沙定試劑,溴沙定雜質(zhì),溴沙定合成,溴沙定中間體,溴沙定密度,溴沙定溶解度,溴沙定旋光度,溴沙定閃點(diǎn),溴沙定熔點(diǎn),溴沙定購(gòu)買(mǎi),
| 產(chǎn)品說(shuō)明 | 溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原生動(dòng)物藥物。 |
| Introduction | 溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)is an antiprotozoal drug. |
| Application1 | |
| Application2 | |
| Application3 |
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)藥理學(xué)：
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原蟲(chóng)藥。Broxaldine抑制艱難梭菌的MIC值為4 µM，并具有抗真菌作用。
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)是一種抗原蟲(chóng)藥。Broxaldine抑制艱難梭菌的MIC值為4 µM，并具有抗真菌作用。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過(guò)程中防止吸入、食入，做好安全防護(hù) |
| Hazra SK, et al. Therapeutic trial of a combination of broxyquinoline and brobenzoxaldine in the treatment of leprosy. Lepr India. 1979 Oct;51(4):505-10. |
| AbdelKhalek A, et al. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo). 2020 Mar 4. |
| A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses PMID 3081428; Human toxicology 1986 Jan; 5(1):35-41 Name matches: broxyquinoline brobenzoxaldine |
| Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination PMID 3081430; Human toxicology 1986 Jan; 5(1):63-4 Name matches: broxyquinoline brobenzoxaldine |
| Broxyquinoline and brobenzoxalidine suspension (Intestopan-AI 307) in childhood diarrhoea. A clinical trial on 533 children PMID 4933138; Indian journal of pediatrics 1970 May; 37(268):177-84 Name mat |
溴沙定(3684-46-6,Broxaldine,Brobenzoxaldine)參考文獻(xiàn)：
1.[Toxicity of hydroxyquinoline derivatives].
Pashov D, Simeonov SP, Drumev D, Pe?nikova Ts, Dzhurov A. Vet Med Nauki. 1980;17(3):118-23.
We studied a 90 day toxicity in dogs of the compound broxyquinoline + broxaldine--5:1 (enteroquin), applied orally and daily in doses of 0.1 and 0.2/kg t/24 h. We established the toxic manifestations during the period after the 15th day of the treatment: leukopenia, neutropenia and lymphocytosis (by 0.2 kg t/24 h). After the second and fifth day we observed a decrease of appetite, depression of the CNS, paralyses, arrhythmia, progressing loss in weight, proteinorrhea (more pronounced with those receiving 0.2/kg t (24 h); lethal consequence with some part of the animals 25% (ba 0.1/kg t) and 50% (by 0.2 kg t). We found out pathohistologically necrobiotic changes in the medulla oblongata and the kidneys, toxic distrophy of the liver, blood-vessel injuries. The toxic changes observed can be interpreted in connection with the presence of a species specific reaction.
2.Letter: Effect of broxyquinoline and broxaldine in leprosy.
Sharma CS. Lancet. 1975 Feb 15;1(7903):405.
3、A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses
R Swain, J S Bapna, A K Das, S Chandrasekar, R P Swaminathan, B Bosco, S Veliath, D P Thombre
Abstract The neurotoxicity of a combination of broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.
1.[Toxicity of hydroxyquinoline derivatives].
Pashov D, Simeonov SP, Drumev D, Pe?nikova Ts, Dzhurov A. Vet Med Nauki. 1980;17(3):118-23.
We studied a 90 day toxicity in dogs of the compound broxyquinoline + broxaldine--5:1 (enteroquin), applied orally and daily in doses of 0.1 and 0.2/kg t/24 h. We established the toxic manifestations during the period after the 15th day of the treatment: leukopenia, neutropenia and lymphocytosis (by 0.2 kg t/24 h). After the second and fifth day we observed a decrease of appetite, depression of the CNS, paralyses, arrhythmia, progressing loss in weight, proteinorrhea (more pronounced with those receiving 0.2/kg t (24 h); lethal consequence with some part of the animals 25% (ba 0.1/kg t) and 50% (by 0.2 kg t). We found out pathohistologically necrobiotic changes in the medulla oblongata and the kidneys, toxic distrophy of the liver, blood-vessel injuries. The toxic changes observed can be interpreted in connection with the presence of a species specific reaction.
2.Letter: Effect of broxyquinoline and broxaldine in leprosy.
Sharma CS. Lancet. 1975 Feb 15;1(7903):405.
3、A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses
R Swain, J S Bapna, A K Das, S Chandrasekar, R P Swaminathan, B Bosco, S Veliath, D P Thombre
Abstract The neurotoxicity of a combination of broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.
對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開(kāi)
SDS 1.0 英文
展開(kāi)
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái)，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
材料.jpg)
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見(jiàn)問(wèn)題
牛血清白蛋白（BSA）常見(jiàn)問(wèn)題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
